title: A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?
abstract: Hyperprolactinaemia is a common adverse event reported in association with treatments used in schizophrenia and bipolar disorder. Recent data are suggestive that hyperprolactinaemia may have a range of significant short-and long-term clinical consequences. The objective of this review is to examine the causes, frequency and clinical consequences of hyperprolactinaemia in the severely mentally ill (SMI) with a focus on patients taking antipsychotic medications. A Medline search was carried out to identify relevant publications. Reference lists from previous review articles were also examined to search for additional data. Hyperprolactinaemia may be one of the most common adverse events associated with some antipsychotic medications. Precise rates with individual drugs had however until recently been poorly categorized. The relationship between hyperprolactinaemia and adverse outcomes in the SMI population appears similar to that in the general population. Adverse outcomes (such as sexual dysfunction) can occur acutely and in the longer term (bone fractures and possibly breast cancer), but the precise link between degree and length of hyperprolactinaemia and adverse outcome remains to be established. In conclusion, hyperprolactinaemia is a common treatment-emergent adverse event of some antipsychotic medications and may have clinical consequences. Physicians must balance the benefits and risks of treatment when determining appropriate therapy for individual patients.
authors.affiliation: Eli Lilly and Company Ltd, Basingstoke, UK. bushe_chris@lilly.com
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Bushe
authors.forename: Andrew
authors.initials: A
authors.lastname: Bradley
authors.forename: John
authors.initials: J
authors.lastname: Pendlebury
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001671:Biochemistry / Q000379:methods*; D017408:Guidelines as Topic; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D001523:Mental Disorders / Q000188:drug therapy; D011388:Prolactin / Q000097:blood / Q000737:chemistry / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D011388:Prolactin